Retatrutide — 10mg

Retatrutide Canada from Maple Research Labs is a lyophilized triple agonist research peptide (GLP-1R / GIPR / GCGR), supplied at 10mg per vial. A sample from the current lot (082126) was analyzed by SideChain Analytics, an independent laboratory in Mississauga, Ontario, at 99.6% chromatographic purity by HPLC-MS/MS with 10.82 mg net peptide against the 10 mg label. Report COA-2026-SC-01772 is published on this page and can be checked on the laboratory’s own site. Compounds are packaged and shipped from British Columbia, with same-day dispatch on orders before 12PM Pacific.

Product Specifications

• Alternative Names: LY-3437943, GGG Tri-Agonist
• Receptor Targets: GLP-1R, GIPR, GCGR
• Molecular Formula: C221H342N46O68
• Molecular Weight: 4731.3 g/mol
• Purity: 99.6% (HPLC-MS/MS, lot 082126)
• Form: Lyophilized powder
• Quantity: 10mg per vial

Retatrutide Peptide Canada Research Summary

Retatrutide (LY-3437943) is a synthetic peptide developed as a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple agonist approach distinguishes retatrutide peptide Canada research products from dual agonists such as tirzepatide (GLP-1R/GIPR) and single agonists such as semaglutide (GLP-1R only).

The rationale for triple agonism is based on preclinical research demonstrating that glucagon receptor activation contributes to energy expenditure and lipid metabolism through distinct mechanisms from those engaged by GLP-1R and GIPR agonism. Published research suggests that the addition of glucagon receptor activity to the GLP-1/GIP agonist profile may produce metabolic effects not achievable through dual agonism alone.

Mechanism of Action Research

Retatrutide’s triple agonist profile engages three distinct G protein-coupled receptors with complementary downstream signaling effects studied in preclinical models. GLP-1R agonism is associated with incretin-mediated insulin secretion and appetite regulation pathways. GIPR agonism contributes to glucose-dependent insulin release and may modulate adipose tissue metabolism. GCGR agonism activates hepatic gluconeogenesis and glycogenolysis pathways, and research suggests it increases energy expenditure through thermogenic mechanisms.

The structural design of retatrutide incorporates modifications that allow simultaneous engagement of all three receptor systems with distinct potency ratios. Published binding affinity studies have characterized the peptide’s relative activity at each receptor, with the highest potency reported at the GIPR, followed by GLP-1R and GCGR.

Preclinical pharmacokinetic studies have examined the peptide’s metabolic stability, half-life characteristics, and receptor occupancy patterns in animal models. The compound incorporates fatty acid modifications designed to extend circulating half-life through albumin binding, similar to approaches used in other long-acting peptide agonists.

Preclinical Study Summary

Retatrutide has been investigated in multiple preclinical metabolic research models. Published studies have examined its effects on glucose homeostasis, lipid metabolism, body composition, and energy expenditure in rodent and non-human primate models. The triple agonist mechanism represents a newer area of incretin biology research compared to established single and dual agonist compounds.

All findings referenced are from preclinical research and early-phase investigations. Researchers should consult primary literature for complete experimental protocols.

References

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023 (PubMed)

Retatrutide Canada Quality Assurance

Retatrutide Canada from Maple Research Labs is released only after independent third-party analysis. A sample from lot 082126 measured 99.6% chromatographic purity by HPLC-MS/MS (report COA-2026-SC-01772), with identity confirmed against a reference standard and 10.82 mg net peptide content against the 10 mg label, a fill accuracy of 108.2%. Each order can be checked against the published certificate before and after purchase.

Storage and Handling

Store lyophilized at -20C. Reconstituted solutions at 2-8C, use within 28 days. Avoid freeze-thaw cycles and light exposure.

Shipping

Ships same-day from our Canadian facility. Temperature-controlled packaging included. Orders before 12PM Pacific on business days are eligible for same-day dispatch from BC.

Certificate of Analysis (COA)

Results are for the sample the laboratory received, reported as measured. The original PDF is also served by the laboratory from its own verification page.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research Articles

• Retatrutide vs Semaglutide: Research Comparison
• Tirzepatide vs Retatrutide: Dual vs Triple Agonist Research
• Semaglutide vs Retatrutide: GLP-1 Receptor Agonist Research
• Certificates of Analysis (COA) Documentation
• Browse All Research Peptides

Frequently Asked Questions

What is the CAS number for Retatrutide?

The CAS registry number for Retatrutide is 2381089-83-2. It is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors.

How is Retatrutide purity verified?

By HPLC-MS/MS at SideChain Analytics, an independent third-party laboratory in Mississauga, Ontario. A sample from the current lot (082126) tested at 99.6% chromatographic purity with identity confirmed against a reference standard (Report COA-2026-SC-01772). The full COA is available as a PDF on this page, and the laboratory confirms the same certificate on its own verification page.

Is Retatrutide available in Canada for research?

Maple Research Labs supplies Retatrutide as a research-use-only lyophilized peptide from British Columbia, with batch-specific third-party COA linked on this page. It is not a Health Canada-authorized drug and is not for human use.

How do I verify the Retatrutide COA?

Open the PDF on this page (report COA-2026-SC-01772), then check it against the laboratory: open the verification page for this report or enter the report number at sidechainanalytics.com. The lab confirms the certificate is authentic and serves the original PDF from its own site.

When does Retatrutide Canada ship?

Orders placed before 12PM Pacific on business days are eligible for same-day dispatch from our BC facility, with tracked Canadian delivery.

How should Retatrutide be stored?

Store lyophilized at -20C. Retatrutide is a large peptide (molecular weight ~4,731 Da) and should be handled with standard peptide storage protocols. Reconstituted solutions at 2-8C, use within 28 days. Avoid freeze-thaw cycles and light exposure.

Related Research Peptides from Maple Research

Researchers may also be interested in Tesamorelin 5MG, Ipamorelin 5MG, and MOTS-C 10MG. All products are shipped same-day from Canada with third-party purity verification.